The drugmaker's revenue rose 17.3 per cent to ₹4,338 crore in Q2 FY27, supported by strong demand for chronic therapies and growth in Bharat Serums and Vaccines' speciality portfolio.
The drugmaker's revenue rose 17.3 per cent to ₹4,338 crore in Q2 FY27, supported by strong demand for chronic therapies and growth in Bharat Serums and Vaccines' speciality portfolio.
<iframe src="https://hindustansphere.com/embed/cluster/b77932b0df3cfd760ad064c552fdef23c5a3436d" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Mankind Pharma Q2 PAT rises 37.7% on strong domestic chronic business"></iframe>
